Mitrovic, Mirjana (54972086700)Mirjana (54972086700)MitrovicPantic, Nikola (57221630977)Nikola (57221630977)PanticBukumiric, Zoran (36600111200)Zoran (36600111200)BukumiricSabljic, Nikica (57221634280)Nikica (57221634280)SabljicVirijevic, Marijana (36969618100)Marijana (36969618100)VirijevicPravdic, Zlatko (57221636770)Zlatko (57221636770)PravdicCvetkovic, Mirjana (58716866000)Mirjana (58716866000)CvetkovicIlic, Nikola (7006245465)Nikola (7006245465)IlicRajic, Jovan (57435044600)Jovan (57435044600)RajicTodorovic-Balint, Milena (55773026600)Milena (55773026600)Todorovic-BalintVidovic, Ana (6701313789)Ana (6701313789)VidovicSuvajdzic-Vukovic, Nada (36446767400)Nada (36446767400)Suvajdzic-VukovicThachil, Jecko (23029666900)Jecko (23029666900)ThachilAntic, Darko (23979576100)Darko (23979576100)Antic2025-06-122025-06-122024https://doi.org/10.1186/s12959-024-00607-6https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190531036&doi=10.1186%2fs12959-024-00607-6&partnerID=40&md5=067f242dac5b3ebf55cc5e28fcbdfa22https://remedy.med.bg.ac.rs/handle/123456789/826Background: Patients with acute myeloid leukemia (AML) are at increased risk of venous thromboembolic events (VTE). However, thromboprophylaxis is largely underused. Objectives: This study aimed to determine possible VTE development risk factors and to develop a novel predictive model. Methods: We conducted a retrospective cohort study of adult patients with newly diagnosed AML. We used univariate and multivariable logistic regression to estimate binary outcomes and identify potential predictors. Based on our final model, a dynamic nomogram was constructed with the goal of facilitating VTE probability calculation. Results: Out of 626 eligible patients with AML, 72 (11.5%) developed VTE during 6 months of follow-up. Six parameters were independent predictors: male sex (odds ratio [OR] 1.82, 95% confidence interval [CI]: 1.077–2.065), prior history of thrombotic events (OR 2.27, 95% CI: 1.4–4.96), international normalized ratio (OR 0.21, 95% CI: 0.05–0.95), Eastern Cooperative Oncology Group performance status (OR 0.71, 95% CI: 0.53–0.94), and intensive therapy (OR 2.05, 95% CI: 1.07–3.91). The C statistics for the model was 0.68. The model was adequately calibrated and internally validated. The decision-curve analysis suggested the use of thromboprophylaxis in patients with VTE risks between 8 and 20%. Conclusion: We developed a novel and convenient tool that may assist clinicians in identifying patients whose VTE risk is high enough to warrant thromboprophylaxis. © The Author(s) 2024.Acute myeloid leukemiaNomogramPredictorThrombosisVenous thromboembolism